Hatteras Venture Partners
SEC exempt reporting adviser (venture capital exemption).
- Website
- http://hatterasvp.com
- HQ
- NC
Hatteras Venture Partners partners with visionary founders to build transformative biotech, medtech, and healthtech companies. Its team includes general partners, partners, venture partners, an operating partner, and a chairman. Portfolio companies include 410 Medical, which develops resuscitation technologies for emergency and critical care, Aer Therapeutics, which develops inhaled therapies for chronic lung diseases, and Wesper, which offers at-home sleep testing.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Series A, Series B, Growth |
| Sectors | Healthtech, Biotech, Medical devices | Not enough dated deals | Biotech, Healthtech, Medical devices |
| Regions | Not stated | Not enough dated deals | NC, MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2001 | 1 | Enterprise SaaS |
| 2007 | 2 | Biotech, Medical devices, Healthtech |
| 2008 | 3 | Healthtech, Biotech, Enterprise SaaS |
| 2009 | 1 | Biotech, Medical devices |
| 2010 | 3 | Healthtech, Biotech, Medical devices |
| 2011 | 2 | Biotech, Healthtech |
| 2012 | 4 | Biotech, Medical devices, Healthtech |
| 2013 | 4 | Biotech, Devtools, Healthtech |
| 2014 | 5 | Biotech, Healthtech, Medical devices |
| 2015 | 13 | Healthtech, Biotech, Medical devices |
| 2016 | 3 | Healthtech, Biotech, Data analytics |
| 2017 | 12 | Biotech, Healthtech, Life sciences and research tools |
| 2018 | 16 | Healthtech, Biotech, Medical devices |
| 2019 | 5 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 3 | Biotech, Consumer, Digital health |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 0 | 1 | 1 | 1 |
| 2011 | 0 | 0 | 0 | 0 | 2 |
| 2012 | 0 | 1 | 1 | 2 | 0 |
| 2013 | 0 | 1 | 3 | 0 | 0 |
| 2014 | 0 | 1 | 0 | 2 | 2 |
| 2015 | 0 | 0 | 5 | 3 | 3 |
| 2016 | 0 | 0 | 1 | 1 | 1 |
| 2017 | 0 | 2 | 3 | 4 | 1 |
| 2018 | 0 | 2 | 5 | 3 | 2 |
| 2019 | 0 | 0 | 3 | 0 | 2 |
| 2020 | 0 | 0 | 1 | 2 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Hatteras Venture Partners VII, LP Hatteras Venture Partners invests in early-stage biotech, medtech, and healthtech companies, partnering with visionary founders to build transformative businesses that advance human medicine and benefit patients. Inferred from the firm's website | 2021 | $135.05M to $250M (Form D) | Late investment period |
| Leaflink C-1 LP | approx. 2021 | Not reported | Follow-ons only |
| L2 Ventures LP | 2021 | $44.88M to $50M (Form D) | Follow-ons only |
03 · People across funds
- Christy Shaffer, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D)
- Clay Thorp, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D)
- Douglas Reed, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D)
- Jeffrey Terrell, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D)
- John Crumpler, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D); L2 Ventures LP (Team)
- Keith Swenson
Leaflink C-1 LP (Named on Form D); L2 Ventures LP (Named on Form D)
- Michael Dial, Manager of General Partner
Hatteras Venture Partners VII, LP (Named on Form D)
- Ben Scruggs, PhD, Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Christy Shaffer, PhD, General Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Clay B. Thorp, General Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Douglas Reed, MD, General Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Fred Goldwater, Venture Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Heather Madsen, PhD, Operating Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Holden Thorp, Venture Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Kenneth B. Lee, Jr., Venture Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Kseniya Simpson, PhD, Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Lauren P. Flickinger, Partner + fund Manager
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Myla Lai-Goldman, MD, Venture Partner
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Ned Sharpless, MD, Managing Director
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
- Sir Andrew Witty, CHAIRMAN
Hatteras Venture Partners VII, LP (Team); L2 Ventures LP (Team)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- http://hatterasvp.com
- https://hatterasvp.com/team
- https://hatterasvp.com/category/portfolio/
- https://hatterasvp.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026